Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Repligen Cp (RGEN)

Repligen Cp (RGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,947,078
  • Shares Outstanding, K 54,771
  • Annual Sales, $ 366,260 K
  • Annual Income, $ 59,930 K
  • 60-Month Beta 0.85
  • Price/Sales 31.80
  • Price/Cash Flow 88.02
  • Price/Book 7.63
Trade RGEN with:

Options Overview

Details
  • Implied Volatility 44.30%
  • Historical Volatility 43.68%
  • IV Percentile 19%
  • IV Rank 17.95%
  • IV High 75.39% on 03/19/20
  • IV Low 37.50% on 08/31/20
  • Put/Call Vol Ratio 2.27
  • Today's Volume 327
  • Volume Avg (30-Day) 321
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 3,189
  • Open Int (30-Day) 3,721

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 0.43
  • Number of Estimates 6
  • High Estimate 0.47
  • Low Estimate 0.40
  • Prior Year 0.32
  • Growth Rate Est. (year over year) +34.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
193.01 +3.55%
on 02/23/21
228.84 -12.66%
on 02/12/21
-14.10 (-6.59%)
since 02/03/21
3-Month
176.25 +13.40%
on 12/08/20
228.84 -12.66%
on 02/12/21
+12.66 (+6.76%)
since 12/03/20
52-Week
78.41 +154.90%
on 03/23/20
228.84 -12.66%
on 02/12/21
+113.22 (+130.66%)
since 03/03/20

Most Recent Stories

More News
Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Fails

Arena's (ARNA) mid-stage study evaluating olorinab in patients with abdominal pain due to irritable bowel syndrome fails to meet primary endpoint.

MRNA : 131.22 (-10.62%)
ARNA : 73.26 (-4.62%)
LXRX : 7.18 (-3.36%)
RGEN : 199.87 (-6.01%)
Repligen Corporation to Present at Barclays Global Healthcare Conference

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the Barclays Global Healthcare Conference being...

RGEN : 199.87 (-6.01%)
Kodiak Sciences (KOD) Misses on Q4 Earnings, KSI-301 in Focus

Kodiak Sciences (KOD) reports wider-than-expected loss in the fourth quarter of 2020. The company is making good progress with the development of its lead pipeline candidate, KSI-301.

LXRX : 7.18 (-3.36%)
RGEN : 199.87 (-6.01%)
NBRV : 1.9400 (+0.52%)
KOD : 115.28 (-7.89%)
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat Estimates

Sarepta (SRPT) Q4 revenues increase year over year. The company is progressing well with its pipeline.

MRNA : 131.22 (-10.62%)
SRPT : 87.11 (-2.05%)
LXRX : 7.18 (-3.36%)
RGEN : 199.87 (-6.01%)
Reata (RETA) Beats on Q4 Earnings, Submits Bardoxolone NDA

Reata (RETA) reports encouraging fourth-quarter results wherein earnings and sales beat estimates. The company files NDA for lead candidate in Alport syndrome. Stock rises.

LXRX : 7.18 (-3.36%)
RGEN : 199.87 (-6.01%)
ABBV : 106.71 (-1.06%)
RETA : 129.86 (+0.41%)
Axsome's (AXSM) Q4 Earnings Miss Estimates, Pipeline in Focus

Axsome (AXSM) reports wider-than-expected loss in the fourth quarter of 2020. The company files an NDA for AXS-05 to treat major depressive disorder.

LXRX : 7.18 (-3.36%)
RGEN : 199.87 (-6.01%)
AXSM : 70.18 (+0.60%)
NBRV : 1.9400 (+0.52%)
Perrigo (PRGO) Misses on Q4 Earnings, to Sell Generic Unit

Perrigo (PRGO) reports dismal fourth-quarter 2020 results. The company signs deal to sell its generic drug business for $1.55 billion. Stock up.

MRNA : 131.22 (-10.62%)
PRGO : 41.28 (-1.92%)
LXRX : 7.18 (-3.36%)
RGEN : 199.87 (-6.01%)
Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q4

Endo's (ENDP) earnings and sales beat estimates in the fourth quarter.

ENDP : 6.85 (-5.26%)
DVAX : 8.49 (-1.74%)
NVAX : 183.61 (-10.86%)
RGEN : 199.87 (-6.01%)
Bausch's (BHC) Q4 Earnings and Revenues Surpass Estimates

Bausch (BHC) reports better-than-expected results for the fourth quarter as the business shows recovery signs from the COVID-19 pandemic.

DVAX : 8.49 (-1.74%)
RGEN : 199.87 (-6.01%)
BHC : 32.56 (+0.87%)
EYEN : 6.28 (+0.80%)
Repligen (RGEN) Q4 Earnings & Sales Top, 2021 Outlook Bright

Repligen (RGEN) reports encouraging fourth-quarter results with sales and earnings beating estimates. The company's guidance for 2021 also beats market expectations. Stock up.

DVAX : 8.49 (-1.74%)
MRNA : 131.22 (-10.62%)
LXRX : 7.18 (-3.36%)
RGEN : 199.87 (-6.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide....

See More

Key Turning Points

3rd Resistance Point 222.73
2nd Resistance Point 218.03
1st Resistance Point 208.95
Last Price 199.87
1st Support Level 195.17
2nd Support Level 190.47
3rd Support Level 181.39

See More

52-Week High 228.84
Last Price 199.87
Fibonacci 61.8% 171.37
Fibonacci 50% 153.62
Fibonacci 38.2% 135.87
52-Week Low 78.41

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar